11 February 2021 - Are oncology therapies recently approved by the US FDA and the EMA associated with clinically meaningful improvements in quality of life?
In this systematic review of approved oncology therapies, 40% of FDA approved and 58% of EMA approved indications had published quality of life evidence.
However, only 6% and 11% of FDA and EMA approved indications, respectively, had clinically meaningful improvements in quality of life beyond minimal clinically important differences.